Medical Research Council, Fajara, Gambia; International Health Unit, University of Antwerp, Belgium; Institute of Tropical Medicine, Antwerp, Belgium.
International Health Unit, University of Antwerp, Belgium.
Clin Microbiol Infect. 2015 Jul;21(7):686.e1-7. doi: 10.1016/j.cmi.2015.02.025. Epub 2015 Mar 6.
The genome of the Plasmodium apicoplast, which has a higher copy number compared with current targets for molecular diagnosis of malaria, appears to be a suitable target for detection of submicroscopic infections that are capable of sustaining transmission. Novel primers targeting a conserved segment of the apicoplast (PFC10_AP|0010:rRNA) were designed and used in a number of different high throughput platforms such as single-step PCR (ssPCR), nested PCR (nPCR) and loop-mediated isothermal amplification (LAMP) for parasite detection. Replicates of ten-fold serial dilutions of Plasmodium falciparum 3D7 DNA, with equivalent parasite density ranges of 200,000 to 0.2 parasites/μL, were used to determine the limit of detection and repeatability of each assay. A panel of 184 archived DNA samples extracted from either EDTA whole blood or dried blood spots, from across West Africa and South East Asia was used to determine the diagnostic performance of the assays. All assays amplified the 2 parasites/μL dilution except the ssPCR, which amplified two of the three replicates. Using an 18S rRNA PCR as reference, the sensitivity was 98% (95% CI 93-100%) for the LAMP assay, 87% (95% CI 79-93%) for ssPCR and 100% (95% CI 97-100%) for nPCR. Specificity was 91% (95% CI 83-96%) for LAMP, 82% (95% CI 72-90%) for ssPCR and 66% (95% CI 54-76%) for nPCR. The apicoplast genome-based nPCR detected more positive samples overall than the reference method. Discrepant samples were confirmed as true positives using a probe-based real-time quantitative PCR assay. The results show that the apicoplast genome is a suitable target for molecular diagnosis of malaria.
疟原虫顶复体基因组的拷贝数高于目前疟疾分子诊断的靶标,似乎是检测能够维持传播的亚微观感染的合适目标。针对顶复体保守区域(PFC10_AP|0010:rRNA)设计了新型引物,并在多种高通量平台上进行了检测,如一步法 PCR(ssPCR)、巢式 PCR(nPCR)和环介导等温扩增(LAMP)。用恶性疟原虫 3D7 DNA 的十倍系列稀释重复样本来确定每种检测方法的检测限和重复性,其寄生虫密度范围为 200,000 至 0.2 个/μL。使用来自西非和东南亚的 EDTA 全血或干血斑中提取的 184 个存档 DNA 样本进行了检测,以确定这些检测方法的诊断性能。除了 ssPCR 外,所有检测方法都扩增了 2 个/μL 稀释度,ssPCR 扩增了三个重复中的两个。与 18S rRNA PCR 作为参考方法相比,LAMP 检测方法的灵敏度为 98%(95%CI 93-100%),ssPCR 的灵敏度为 87%(95%CI 79-93%),nPCR 的灵敏度为 100%(95%CI 97-100%)。LAMP 的特异性为 91%(95%CI 83-96%),ssPCR 的特异性为 82%(95%CI 72-90%),nPCR 的特异性为 66%(95%CI 54-76%)。基于顶复体基因组的 nPCR 检测到的阳性样本总体上比参考方法多。使用基于探针的实时定量 PCR 检测方法对有差异的样本进行了确证,结果显示顶复体基因组是疟疾分子诊断的合适靶标。